HIV Drugs Market

HIV Drugs Market - Global Industry Assessment & Forecast

Healthcare

# Pages:

143

Base Year:

2022

Mar - 2023

Format:

Report Code:

VMR-2036

Segments Covered

By Drug Classes Integrase Inhibitors, Non- Nucleoside Reverse Transcriptase Inhibitors (NRTIs), Combination HIV Medicines, Other Drug Classes
By Distribution Channels Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channels
By Region North America, Europe, Asia Pacific, Latin America, Middle East & Africa

Standard License

$ 4299 USD

Multi User License

$ 6599 USD

Enterprise License

$ 6999 USD

Snapshot

Base Year:	2022
Forecast Years:	2023 - 2030
Historical Years:	2017 - 2021
Revenue 2022:	USD 31.3 Billlion
Revenue 2030:	USD 40.3 Billlion
Revenue CAGR (2023 - 2030):	3.7%
Fastest Growing Region (2023 - 2030)	Asia Pacific
Largest Region (2022):	North America

Customization Offered

Cross-segment Market Size and Analysis for Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market Dynamics
Region Level Market Share
Import Export Analysis
Production Analysis
Others Request Customization Speak To Analyst

Executive Dashboard
1. Strategic Imperatives
Premium Insights
1. Top 3 Trends to Watch
2. Demand and Supply Trends
3. Top 3 Strategies Followed by Major Players
4. Top 3 Predictions by Vantage Market Research
5. Top Investment Pockets
6. Insights from Primary Respondents
Global HIV Drugs Market - Segment Analysis
1. Overview
2. Global HIV Drugs Market, 2016 - 2028 (USD Million)
3. Global HIV Drugs Market - by Drug Classes
  1. By Integrase Inhibitors
  2. By Non- Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
  3. By Combination HIV Medicines
  4. By Other Drug Classes
4. Global HIV Drugs Market - by Distribution Channels
  1. By Hospital Pharmacies
  2. By Retail Pharmacies
  3. By Online Pharmacies
  4. By Other Distribution Channels
5. Global HIV Drugs Market - by region
  1. North America
  2. Europe
  3. Asia Pacific
  4. Latin America
  5. Middle East & Africa
6. Market comparative analysis
North America HIV Drugs Market - Segment Analysis
1. Overview
2. North America HIV Drugs Market, 2016 - 2028 (USD Million)
3. North America HIV Drugs Market, by Drug Classes
  1. By Integrase Inhibitors
  2. By Non- Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
  3. By Combination HIV Medicines
  4. By Other Drug Classes
4. North America HIV Drugs Market, by Distribution Channels
  1. By Hospital Pharmacies
  2. By Retail Pharmacies
  3. By Online Pharmacies
  4. By Other Distribution Channels
5. North America HIV Drugs Market, by Country
  1. U.S.
    1. U.S. HIV Drugs Market, By Drug Classes
      1. By Integrase Inhibitors
      2. By Non- Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
      3. By Combination HIV Medicines
      4. By Other Drug Classes
    2. U.S. HIV Drugs Market, By Distribution Channels
      1. By Hospital Pharmacies
      2. By Retail Pharmacies
      3. By Online Pharmacies
      4. By Other Distribution Channels
  2. Canada
    1. Canada HIV Drugs Market, By Drug Classes
      1. By Integrase Inhibitors
      2. By Non- Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
      3. By Combination HIV Medicines
      4. By Other Drug Classes
    2. Canada HIV Drugs Market, By Distribution Channels
      1. By Hospital Pharmacies
      2. By Retail Pharmacies
      3. By Online Pharmacies
      4. By Other Distribution Channels
  3. Mexico
    1. Mexico HIV Drugs Market, By Drug Classes
      1. By Integrase Inhibitors
      2. By Non- Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
      3. By Combination HIV Medicines
      4. By Other Drug Classes
    2. Mexico HIV Drugs Market, By Distribution Channels
      1. By Hospital Pharmacies
      2. By Retail Pharmacies
      3. By Online Pharmacies
      4. By Other Distribution Channels
Europe HIV Drugs Market - Segment Analysis
1. Overview
2. Europe HIV Drugs Market, 2016 - 2028 (USD Million)
3. Europe HIV Drugs Market, by Drug Classes
  1. By Integrase Inhibitors
  2. By Non- Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
  3. By Combination HIV Medicines
  4. By Other Drug Classes
4. Europe HIV Drugs Market, by Distribution Channels
  1. By Hospital Pharmacies
  2. By Retail Pharmacies
  3. By Online Pharmacies
  4. By Other Distribution Channels
5. Europe HIV Drugs Market, by Country
  1. Germany
    1. Germany HIV Drugs Market, By Drug Classes
      1. By Integrase Inhibitors
      2. By Non- Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
      3. By Combination HIV Medicines
      4. By Other Drug Classes
    2. Germany HIV Drugs Market, By Distribution Channels
      1. By Hospital Pharmacies
      2. By Retail Pharmacies
      3. By Online Pharmacies
      4. By Other Distribution Channels
  2. UK
    1. UK Market, By Drug Classes
      1. By Integrase Inhibitors
      2. By Non- Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
      3. By Combination HIV Medicines
      4. By Other Drug Classes
    2. UK Market, By Distribution Channels
      1. By Hospital Pharmacies
      2. By Retail Pharmacies
      3. By Online Pharmacies
      4. By Other Distribution Channels
  3. France
    1. France HIV Drugs Market, By Drug Classes
      1. By Integrase Inhibitors
      2. By Non- Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
      3. By Combination HIV Medicines
      4. By Other Drug Classes
    2. France HIV Drugs Market, By Distribution Channels
      1. By Hospital Pharmacies
      2. By Retail Pharmacies
      3. By Online Pharmacies
      4. By Other Distribution Channels
  4. Spain
    1. Spain HIV Drugs Market, By Drug Classes
      1. By Integrase Inhibitors
      2. By Non- Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
      3. By Combination HIV Medicines
      4. By Other Drug Classes
    2. Spain HIV Drugs Market, By Distribution Channels
      1. By Hospital Pharmacies
      2. By Retail Pharmacies
      3. By Online Pharmacies
      4. By Other Distribution Channels
  5. Italy
    1. Italy HIV Drugs Market, By Drug Classes
      1. By Integrase Inhibitors
      2. By Non- Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
      3. By Combination HIV Medicines
      4. By Other Drug Classes
    2. Italy HIV Drugs Market, By Distribution Channels
      1. By Hospital Pharmacies
      2. By Retail Pharmacies
      3. By Online Pharmacies
      4. By Other Distribution Channels
  6. BENELUX
    1. BENELUX HIV Drugs Market, By Drug Classes
      1. By Integrase Inhibitors
      2. By Non- Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
      3. By Combination HIV Medicines
      4. By Other Drug Classes
    2. BENELUX HIV Drugs Market, By Distribution Channels
      1. By Hospital Pharmacies
      2. By Retail Pharmacies
      3. By Online Pharmacies
      4. By Other Distribution Channels
  7. Rest of Europe
    1. Rest Of Europe HIV Drugs Market, By Drug Classes
      1. By Integrase Inhibitors
      2. By Non- Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
      3. By Combination HIV Medicines
      4. By Other Drug Classes
    2. Rest Of Europe HIV Drugs Market, By Distribution Channels
      1. By Hospital Pharmacies
      2. By Retail Pharmacies
      3. By Online Pharmacies
      4. By Other Distribution Channels
Asia Pacific HIV Drugs Market - Segment Analysis
1. Overview
2. Asia Pacific HIV Drugs Market, 2016 - 2028 (USD Million)
3. Asia Pacific HIV Drugs Market, by Drug Classes
  1. By Integrase Inhibitors
  2. By Non- Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
  3. By Combination HIV Medicines
  4. By Other Drug Classes
4. Asia Pacific HIV Drugs Market, by Distribution Channels
  1. By Hospital Pharmacies
  2. By Retail Pharmacies
  3. By Online Pharmacies
  4. By Other Distribution Channels
5. Asia Pacific HIV Drugs Market, by Country
  1. China
    1. China HIV Drugs Market, By Drug Classes
      1. By Integrase Inhibitors
      2. By Non- Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
      3. By Combination HIV Medicines
      4. By Other Drug Classes
    2. China HIV Drugs Market, By Distribution Channels
      1. By Hospital Pharmacies
      2. By Retail Pharmacies
      3. By Online Pharmacies
      4. By Other Distribution Channels
  2. Japan
    1. Japan HIV Drugs Market, By Drug Classes
      1. By Integrase Inhibitors
      2. By Non- Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
      3. By Combination HIV Medicines
      4. By Other Drug Classes
    2. Japan HIV Drugs Market, By Distribution Channels
      1. By Hospital Pharmacies
      2. By Retail Pharmacies
      3. By Online Pharmacies
      4. By Other Distribution Channels
  3. India
    1. India HIV Drugs Market, By Drug Classes
      1. By Integrase Inhibitors
      2. By Non- Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
      3. By Combination HIV Medicines
      4. By Other Drug Classes
    2. India HIV Drugs Market, By Distribution Channels
      1. By Hospital Pharmacies
      2. By Retail Pharmacies
      3. By Online Pharmacies
      4. By Other Distribution Channels
  4. South Korea
    1. South Korea HIV Drugs Market, By Drug Classes
      1. By Integrase Inhibitors
      2. By Non- Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
      3. By Combination HIV Medicines
      4. By Other Drug Classes
    2. South Korea HIV Drugs Market, By Distribution Channels
      1. By Hospital Pharmacies
      2. By Retail Pharmacies
      3. By Online Pharmacies
      4. By Other Distribution Channels
  5. South East Asia
    1. South East Asia HIV Drugs Market, By Drug Classes
      1. By Integrase Inhibitors
      2. By Non- Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
      3. By Combination HIV Medicines
      4. By Other Drug Classes
    2. South East Asia HIV Drugs Market, By Distribution Channels
      1. By Hospital Pharmacies
      2. By Retail Pharmacies
      3. By Online Pharmacies
      4. By Other Distribution Channels
  6. Rest of Asia Pacific
    1. Rest of Asia Pacific HIV Drugs Market, By Drug Classes
      1. By Integrase Inhibitors
      2. By Non- Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
      3. By Combination HIV Medicines
      4. By Other Drug Classes
    2. Rest of Asia Pacific HIV Drugs Market, By Distribution Channels
      1. By Hospital Pharmacies
      2. By Retail Pharmacies
      3. By Online Pharmacies
      4. By Other Distribution Channels
Latin America HIV Drugs Market - Segment Analysis
1. Overview
2. Latin America HIV Drugs Market, 2016 - 2028 (USD Million)
3. Latin America HIV Drugs Market, by Drug Classes
  1. By Integrase Inhibitors
  2. By Non- Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
  3. By Combination HIV Medicines
  4. By Other Drug Classes
4. Latin America HIV Drugs Market, by Distribution Channels
  1. By Hospital Pharmacies
  2. By Retail Pharmacies
  3. By Online Pharmacies
  4. By Other Distribution Channels
5. Latin America HIV Drugs Market, by Country
  1. Brazil
    1. Brazil HIV Drugs Market, By Drug Classes
      1. By Integrase Inhibitors
      2. By Non- Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
      3. By Combination HIV Medicines
      4. By Other Drug Classes
    2. Brazil HIV Drugs Market, By Distribution Channels
      1. By Hospital Pharmacies
      2. By Retail Pharmacies
      3. By Online Pharmacies
      4. By Other Distribution Channels
  2. Argentina
    1. Argentina HIV Drugs Market, By Drug Classes
      1. By Integrase Inhibitors
      2. By Non- Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
      3. By Combination HIV Medicines
      4. By Other Drug Classes
    2. Argentina HIV Drugs Market, By Distribution Channels
      1. By Hospital Pharmacies
      2. By Retail Pharmacies
      3. By Online Pharmacies
      4. By Other Distribution Channels
  3. Rest of Latin America
    1. Rest of Latin America HIV Drugs Market, By Drug Classes
      1. By Integrase Inhibitors
      2. By Non- Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
      3. By Combination HIV Medicines
      4. By Other Drug Classes
    2. Rest of Latin America HIV Drugs Market, By Distribution Channels
      1. By Hospital Pharmacies
      2. By Retail Pharmacies
      3. By Online Pharmacies
      4. By Other Distribution Channels
Middle East & Africa HIV Drugs Market - Segment Analysis
1. Overview
2. Middle East & Africa HIV Drugs Market, 2016 - 2028 (USD Million)
3. Middle East & Africa HIV Drugs Market, by Drug Classes
  1. By Integrase Inhibitors
  2. By Non- Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
  3. By Combination HIV Medicines
  4. By Other Drug Classes
4. Middle East & Africa HIV Drugs Market, by Distribution Channels
  1. By Hospital Pharmacies
  2. By Retail Pharmacies
  3. By Online Pharmacies
  4. By Other Distribution Channels
5. Middle East & Africa HIV Drugs Market, by Country
  1. GCC Countries
    1. GCC Countries HIV Drugs Market, By Drug Classes
      1. By Integrase Inhibitors
      2. By Non- Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
      3. By Combination HIV Medicines
      4. By Other Drug Classes
    2. GCC Countries HIV Drugs Market, By Distribution Channels
      1. By Hospital Pharmacies
      2. By Retail Pharmacies
      3. By Online Pharmacies
      4. By Other Distribution Channels
  2. South Africa
    1. South Africa HIV Drugs Market, By Drug Classes
      1. By Integrase Inhibitors
      2. By Non- Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
      3. By Combination HIV Medicines
      4. By Other Drug Classes
    2. South Africa HIV Drugs Market, By Distribution Channels
      1. By Hospital Pharmacies
      2. By Retail Pharmacies
      3. By Online Pharmacies
      4. By Other Distribution Channels
  3. Rest of Middle East & Africa
    1. Rest of Middle East & Africa HIV Drugs Market, By Drug Classes
      1. By Integrase Inhibitors
      2. By Non- Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
      3. By Combination HIV Medicines
      4. By Other Drug Classes
    2. Rest of Middle East & Africa HIV Drugs Market, By Distribution Channels
      1. By Hospital Pharmacies
      2. By Retail Pharmacies
      3. By Online Pharmacies
      4. By Other Distribution Channels
Key Market Dynamics
1. Introduction
2. Market Drivers
3. Market Restraints
4. Market Opportunities
5. Porter's Five Forces Analysis
6. PEST Analysis
7. Regulatory Landscape
8. Technology Landscape
9. Regional Market Trends
COVID 19 Impact Analysis
1. Key strategies undertaken by companies to tackle COVID-19
2. Short term dynamics
3. Long term dynamics
Marketing Stratagy Analysis
1. Marketing Channel
2. Direct Marketing
3. Indirect Marketing
4. Marketing Channel Development Trends
Competative Landscape
1. Competition Matrix - 2021
2. Company Market Share Analysis - 2021
3. Key Company Activities, 2018 - 2021
4. Strategic Developments - Heat Map Analysis
5. Company Offering Evaluation
6. Company Regional Presence Evaluation
Company Profiles
1. ViiV Healthcare (U.S.)
2. Gilead Sciences Inc. (U.S.)
3. Glaxo Smith Kline PLC (U.K.)
4. Merck Sharp & Dohme Corp. (France)
5. Bristol-Myers Squibb Company (U.S.)
6. Janssen Pharmaceuticals Inc. (Johnson & Johnson) (Belgium)
7. Boehringer Ingelheim International GmbH (Germany)
8. AbbVie Inc. (U.S.)
9. Genentech Inc. (F. Hoffmann-La Roche AG) (U.S.)
10. Mylan N.V. (U.S.)
Key Primary Respondents - VERBATIM
Discussion Guide
Customization Offered
Annexure
List of Figures
List of Tables
List of Abbreviations

Vantage Market Research | 23-Mar-2023

HIV Drugs Market to Reach Valuation of USD 40.3 Billion by 2028 – Increasing Number of New Product Launches and Rising Drug Approvals Drives the Market

FAQ

Frequently Asked Question

What is the global demand for HIV Drugs in terms of revenue?

The global HIV Drugs valued at USD 31.3 Billlion in 2022 and is expected to reach USD 40.3 Billlion in 2030 growing at a CAGR of 3.7%.

Which are the prominent players in the market?

The prominent players in the market are ViiV Healthcare (U.S.), Gilead Sciences Inc. (U.S.), Glaxo Smith Kline PLC (U.K.), Merck Sharp & Dohme Corp. (France), Bristol-Myers Squibb Company (U.S.), Janssen Pharmaceuticals Inc. (Johnson & Johnson) (Belgium), Boehringer Ingelheim International GmbH (Germany), AbbVie Inc. (U.S.), Genentech Inc. (F. Hoffmann-La Roche AG) (U.S.), Mylan N.V. (U.S.).

At what CAGR is the market projected to grow within the forecast period?

The market is project to grow at a CAGR of 3.7% between 2023 and 2030.

What are the driving factors fueling the growth of the market.

The driving factors of the HIV Drugs include
- Increase in number of HIV infected patients worldwide

Which region accounted for the largest share in the market?

North America was the leading regional segment of the HIV Drugs in 2022.

HIV Drugs Market

HIV Drugs Market - Global Industry Assessment & Forecast

Healthcare

Segments Covered

Snapshot

Customization Offered

FAQ

Frequently Asked Question

What is the global demand for HIV Drugs in terms of revenue?

Which are the prominent players in the market?

At what CAGR is the market projected to grow within the forecast period?

What are the driving factors fueling the growth of the market.

Which region accounted for the largest share in the market?

Vantage Market Research

Products & Services

Media

Contact Us

HIV Drugs Market

HIV Drugs Market - Global Industry Assessment & Forecast

Healthcare

Segments Covered

Snapshot

Customization Offered

FAQ

Frequently Asked Question

What is the global demand for HIV Drugs in terms of revenue?

Which are the prominent players in the market?

At what CAGR is the market projected to grow within the forecast period?

What are the driving factors fueling the growth of the market.

Which region accounted for the largest share in the market?

Related Reports

Request Sample Report for HIV Drugs Market

Vantage Point Interactive Dashboard